Daiichi firm on Ranbaxy buyout despite US FDA action
Daiichi Sankyo has said that the company has not made any changes in their acquisition plans for Ranbaxy. The company also said that they knew that US FDA has investigated the Ranbaxy facilities. At this stage Daiichi Sankyo and Ranbaxy will remain two independent companies, it said.
